# NCT06377852 (NCT06377852)

> The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06377852
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: American Society of Clinical Oncology
- Conditions: Metastatic Breast Cancer
- Interventions: Palbociclib 125mg; Ribociclib 600mg; Ribociclib; Palbociclib
- Enrollment: 500
- Primary outcome: Time to Treatment Discontinuation (TTD)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3
- Bluesky threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06377852